Johnson & Johnson unveiled phase 3 findings at the European Hematology Association Congress 2026 in Stockholm, highlighting the growing impact of bispecific antibodies in multiple myeloma treatment. Results from the MonumenTAL-3 phase 3 study showed that Talvey combined with Darzalex
